Skip to main content
Navigate Up
Sign In

University of Colorado Denver | Anschutz Medical Campus

University of Colorado Denver, Newsroom

Our Colleagues

Paul Bunn: Honored among “Giants of Cancer Care”

8/8/2014
CU Cancer Center investigator Paul A. Bunn, Jr., MD, was named one of the 2014 “Giants of Cancer Care” by OncLive, the official home of Oncology & Biotech News, OncologyLive, Urologists in Cancer Care, Oncology Nursing News, Oncology Business Management and Contemporary Oncology.
 
Bunn is one of 16 luminaries nationwide selected by oncology industry peers for remarkable achievements in research and/or clinical practice. The Giants of Cancer Care awards recognize and celebrate individuals who have achieved landmark success within the field of oncology. The honorees were recognized during ceremony May 30 in Chicago.
 
“It is our distinct privilege to honor these unsung medical heroes. It is our mission to continue recognizing the leaders in the oncology field for their remarkable achievements in research and clinical practice,” said OncLive Chairman and CEO Mike Hennessy.
 
Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, over 122 reviews and editorials, and 90 book chapters on lung cancer. His studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research in lung cancer.
 
Giants are chosen by an exclusive advisory board of 29 oncology educators, clinicians and researchers. Advisory Board members have dedicated their time to the program, providing guidance to OncLive as it further develops the program and, most importantly, selects the oncologists who will be named Giants.
 
In evaluating criteria for selection to the inaugural class of Giants, the Advisory Board considered individuals who have made a significant contribution to patient care, clinical trials or translational research.
 
###

Share